HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recent advances in the design and optimization of adenosine A2A receptor antagonists.

Abstract
In recent years, the adenosine A2A receptor has gained interest as a potential therapeutic target for alleviating the symptoms of Parkinson's disease. Adenosine A2A receptor antagonists are orally effective in a variety of rodent models of Parkinson's disease. Traditionally, adenosine A2A, receptor antagonists are divided into two general classes, xanthine or non-xanthine derivatives. Extensive optimization among the xanthine derivatives has already led to the clinical candidate KW-6002 (Kyowa Hakko Kogyo Co Ltd). However, there is increasing interest among researchers in this field to explore other classes of compounds as potential antagonists for this particular receptor. This review highlights the more recent developments in the design and optimization of non-xanthine derivatives as adenosine A2A receptor antagonists.
AuthorsChi B Vu
JournalCurrent opinion in drug discovery & development (Curr Opin Drug Discov Devel) Vol. 8 Issue 4 Pg. 458-68 (Jul 2005) ISSN: 1367-6733 [Print] England
PMID16022182 (Publication Type: Journal Article, Review)
Chemical References
  • Adenosine A2 Receptor Antagonists
  • Triazines
  • Triazoles
Topics
  • Adenosine A2 Receptor Antagonists
  • Animals
  • Drug Design
  • Humans
  • Triazines (chemistry, pharmacology)
  • Triazoles (chemistry, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: